DALBAVANCIN
Generic: DALBAVANCIN HYDROCHLORIDE
Long Grove PharmaceuticalsManufacturer
INTRAVENOUSRoute
DALBAVANCIN HYDROCHLORIDEActive Substance
2026-02-26Original Approval
DALBAVANCIN is FDA application ANDA218602, sponsored by LONG GROVE PHARMS. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
OFF LABEL USE
43 reports
2
DRUG INEFFECTIVE
38 reports
3
ACUTE KIDNEY INJURY
33 reports
4
VOMITING
29 reports
5
PYREXIA
26 reports
6
INFUSION RELATED REACTION
18 reports
7
DECREASED APPETITE
17 reports
8
MALAISE
17 reports
9
DIARRHOEA
16 reports
10
ERYTHEMA
16 reports